Company Overview

BiomX Inc. is a clinical-stage biotechnology company focused on developing bacteriophage-based therapeutics designed to target and destroy pathogenic bacteria while preserving the beneficial microbiome. The company operates within the biopharmaceutical and microbiome therapeutics industries, with a core emphasis on infectious and inflammatory diseases where antibiotic resistance or limited treatment options exist. BiomX’s approach leverages proprietary phage discovery and development technologies to create targeted antibacterial treatments.

The company’s primary value is driven by its clinical development pipeline rather than product revenue, as it does not have approved commercial products. Key programs include BX004, targeting Pseudomonas aeruginosa infections in cystic fibrosis patients, and BX211, targeting Staphylococcus aureus in atopic dermatitis. BiomX was founded in 2015 and became a publicly traded company in 2019 through a merger with a special purpose acquisition company, subsequently operating as a U.S.-listed entity while maintaining substantial research operations in Israel.

Business Operations

BiomX operates as a single reportable operating segment focused on research and development of phage-based therapies. Revenue generation to date has primarily consisted of research collaborations and grant-related income, with the majority of expenditures directed toward clinical trials, preclinical research, and platform development. The company’s operations span early discovery through Phase 2 clinical development.

The company conducts research and development through BiomX Ltd., its primary operating subsidiary in Israel, which houses laboratory facilities and scientific personnel. Clinical development, regulatory strategy, and corporate functions are managed through U.S. operations. BiomX controls a proprietary phage discovery and manufacturing platform and has not disclosed reliance on any single material commercial partnership for revenue generation; data inconclusive based on available public sources regarding material joint ventures.

Strategic Position & Investments

BiomX’s strategy centers on advancing its lead clinical assets toward later-stage development while expanding its phage platform to additional bacterial targets. Growth initiatives include progressing BX004 and BX211 through clinical milestones and exploring additional indications where precision antibacterial therapy may provide a competitive advantage over broad-spectrum antibiotics.

The company’s investments are primarily internal, focused on R&D, clinical trials, and intellectual property development rather than external acquisitions. BiomX has not reported material acquisitions of other companies but continues to invest in expanding its phage library and manufacturing capabilities. Its strategic positioning emphasizes first-mover advantages in regulated, systemically administered phage therapies, an area with limited direct competition.

Geographic Footprint

BiomX operates primarily across North America and Israel, with its corporate headquarters in the United States and significant research and development facilities in Israel. Clinical trials are conducted in multiple countries, including sites in the United States and Europe, depending on study design and regulatory requirements.

While the company does not maintain commercial operations, its international footprint reflects the global nature of clinical research and regulatory engagement. BiomX’s influence outside its core regions is primarily through clinical trial sites and scientific collaborations rather than permanent operational infrastructure.

Leadership & Governance

BiomX was founded by Jonathan Solomon, who has played a central role in shaping the company’s scientific and strategic direction. The leadership team emphasizes a science-driven strategy focused on clinical validation, regulatory rigor, and long-term platform value creation.

Key executives include:

• Jonathan Solomon – Chief Executive Officer and Chairman of the Board
• David Malka – Chief Financial Officer
• Erez Netzer, M.D. – Chief Medical Officer (data inconclusive based on available public sources regarding current title continuity)

The company is governed by a board of directors with experience in biotechnology, finance, and clinical development, aligning governance practices with U.S. public company standards.